In a major step forward for accessible and precision-driven cancer care in India, AIIMS Jammu has inaugurated the Centre for Advanced Genomics & Precision Medicine. The launch marks a significant milestone in the integration of cutting-edge genomic technology with clinical oncology.
NextSeq 2000 Sequencer Begins Operations
As reported by bwhealthcareworld, the Centre commenced operations with the installation of the Illumina NextSeq 2000 sequencing system, a state-of-the-art Next Generation Sequencing (NGS) machine. This addition reinforces AIIMS Jammu’s commitment to offering high-end molecular diagnostics to cancer patients.
Dignitaries Grace the Inauguration
The inauguration ceremony witnessed the presence of several eminent leaders from academia and healthcare, including:
- Prof. (Dr) Shakti Kumar Gupta, Executive Director and CEO, AIIMS Jammu
- Lt Gen Dr. Sunil Kant, Dean Research and Medical Superintendent
- Prof. Dr. Meeta Gupta, Dean (Academics)
- Prof. Dr. Shabab L. Angurana, Associate Dean (Research)
- Shailender Slathia, Registrar
- Dr. Poonam Sharma, Head of Pathology
- Dr. Sudharshan Elangovan, Vice President – Global Operations, 4baseCare
A Commitment to Personalized Patient Care
Prof. (Dr) Shakti Kumar Gupta emphasized the human aspect of medical treatment, stating,
“For every patient we treat, we are treating a mother, a father, a sister, or a brother. This partnership is our promise to every family who walks through our doors — that we will do everything in our power to bring them the care they deserve.”
Partnership with 4baseCare Brings Precision Oncology to the Forefront
Developed in collaboration with 4baseCare, the Centre leverages NGS technology to offer comprehensive genomic profiling for cancer patients. This enables clinicians to design highly individualized and targeted therapies based on each patient’s unique molecular makeup.
Dr. Sudharshan Elangovan, VP – Global Operations at 4baseCare, highlighted the Centre’s transformative potential:
“By combining advanced genomic data with AI-powered diagnostics, we can improve early detection, refine therapy selection, and reduce ineffective treatments. The goal is better outcomes and a higher quality of life for patients.”
Making Genomic Testing More Affordable and Accessible
Traditionally, the high cost of genomic testing limited its use in India. However, this initiative aims to deliver affordable, high-quality NGS-based tests, ensuring broader access to precision oncology for patients across socio-economic backgrounds.
A National Referral Hub for Advanced Diagnostics
Looking ahead, the Centre will function as a referral hub, accepting samples from across India. This will make advanced molecular diagnostics available to patients in remote and underserved areas, ensuring that location is no longer a barrier to cutting-edge cancer care.